Detalhe da pesquisa
1.
Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14-valent recombinant human papillomavirus vaccine.
J Med Virol
; 95(8): e29050, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37635425
2.
Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study.
BMC Cancer
; 22(1): 1104, 2022 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307775
3.
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.
Hematol Oncol
; 40(5): 930-940, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35858181
4.
Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
Haemophilia
; 28(6): e199-e208, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35802040
5.
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.
Chin J Cancer Res
; 34(6): 601-611, 2022 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36714342
6.
Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.
Haemophilia
; 27(5): 814-822, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34089210
7.
Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice.
Acta Pharmacol Sin
; 37(3): 408-14, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26806305
8.
Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma.
Chin J Cancer Res
; 28(2): 197-208, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27199517
9.
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase â ¡ study.
EBioMedicine
; 100: 104966, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38217945
10.
Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial.
EClinicalMedicine
; 64: 102195, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731938
11.
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma.
Cancer Biol Med
; 2022 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35014769